1 Great Valley Parkway
Suite 24
Malvern, PA 19355
United States
484 320 2930
https://www.telabio.com
Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 227
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Antony Koblish | Co-founder, President, CEO & Director | 1,03M | N/D | 1966 |
Mr. Roberto E. Cuca J.D. | CFO & COO | 674,78k | N/D | 1968 |
Mr. Paul Talmo | Chief Technology Officer | 595,67k | N/D | 1972 |
Ms. Megan Smeykal | VP, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer | N/D | N/D | 1976 |
Mr. D. Taylor Ocasio | General Counsel & Corporate Secretary | N/D | N/D | N/D |
Ms. Jennifer Lou Armstrong | Senior Vice President of Human Resources | N/D | N/D | 1970 |
Mr. Gregory A. Firestone | Chief Commercial Officer | N/D | N/D | 1959 |
Mr. Michael Leonard | Senior Vice President of Technical Operations | N/D | N/D | N/D |
Mr. Peter C. Murphy | Chief Commercial Officer | 542,34k | N/D | 1973 |
Louisa Smith | Investor Relations Contact Officer | N/D | N/D | N/D |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
L'ISS Governance QualityScore di TELA Bio, Inc. al 1 giugno 2024 è 9. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 10.